Corrigendum: *In vivo* detection of metabolic $^2$H-incorporation upon ingestion of $^2$H$_2$O

In the article titled “*In vivo* detection of metabolic $^2$H-incorporation upon ingestion of $^2$H$_2$O” (DOI 10.1097/JBR.0000000000000121), the information in the “Conflicts of Interest” section is incomplete. The complete and correct information about the Conflicts of Interest is as follows:

PS and KDS are cofounders of Deep Breath Intelligence AG (Switzerland), which develops breath-based diagnostic tools. KDS is consultant for Deep Breath Intelligence AG (Switzerland). All the other authors declare no competing interests. The concept of monitoring metabolic $^2$H-incorporation non-invasively and *in vivo* via SESI-HRMS has been incorporated as a patent with the title “Mass spectrometry Method and System” in the China Intellectual Property Office PCT/CN2022/075436, filed on February 8th, 2022.

The authors apologize for any inconvenience this correction may cause for readers and editors of *Journal of Bio-X Research*.

**Reference**

[1] Arnold K, Chen X, Zhang H, et al. In vivo detection of metabolic $^2$H-incorporation upon ingestion of $^2$H$_2$O. J Bio-X Res 2022;5:81–89.